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Abstract
Background and aims: Rapid and accurate cancer staging following diagnosis underpins patient management,
in particular the identification of distant metastatic disease. Current staging guidelines recommend sequential
deployment of various imaging platforms such as computerised tomography (CT) and positron emission
tomography (PET) which can be time and resource intensive and onerous for patients. Recent studies demonstrate
that whole body magnetic resonance Imaging (WB-MRI) may stage cancer efficiently in a single visit, with
potentially greater accuracy than current staging investigations. The Streamline trials aim to evaluate whether
WB-MRI increases per patient detection of metastases in non-small cell lung and colorectal cancer compared to
standard staging pathways.
Methods: The Streamline trials are multicentre, non-randomised, single-arm, prospective diagnostic accuracy
studies with a novel design to capture patient management decisions during staging pathways. The two trials
recruit adult patients with proven or highly suspected new diagnosis of primary colorectal (Streamline C) or non-
small cell lung cancer (Streamline L) referred for staging. Patients undergo WB-MRI in addition to standard staging
investigations. Strict blinding protocols are enforced for those interpreting the imaging. A first major treatment
decision is made by the multi-disciplinary team prior to WB-MRI revelation based on standard staging investigations
only, then based on the WB-MRI and any additional tests precipitated by WB-MRI, and finally based on all available
test results. The reference standard is derived by a multidisciplinary consensus panel who assess 12 months of
follow-up data to adjudicate on the TNM stage at diagnosis. Health psychology assessment of patients’ experiences
of the cancer staging pathway will be undertaken via interviews and questionnaires. A cost (effectiveness) analysis
of WB-MRI compared to standard staging pathways will be performed.
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Discussion: We describe a novel approach to radiologist and clinician blinding to ascertain the ‘true’ diagnostic
accuracy of differing imaging pathways and discuss our approach to assessing the impact of WB-MRI on clinical
decision making in real-time. The Streamline trials will compare WB-MRI and standard imaging pathways in the
same patients, thereby informing the most accurate and efficient approach to staging.
Trial registration: Streamline C ISRCTN43958015 (registered 25/7/2012). Streamline L ISRCTN50436483 (registered
31/7/2012).
Keywords: Colorectal cancer, Lung cancer, Staging, Computed tomography, Whole body magnetic resonance
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Background
Lung and colorectal cancer are the second and third
most common malignancies in the UK, each accounting
for 16% of all new cancer diagnoses; approximately
87,000 patients diagnosed per year [1]. Treatment
decisions for both pivot on rapid and accurate tumour
staging following diagnosis. In particular, detection of
metastatic disease (i.e. disease which has disseminated
beyond the primary tumour into distant organ sites
such as bone, liver and brain) is vital for appropriate
management.
In colorectal cancer, 50% of patients undergoing pri-
mary surgery with curative intent, relapse subsequently
with metastatic disease, often within 12 months [2], in
part reflecting sub-optimal staging following diagnosis.
In lung cancer, over 20% of patients undergoing curative
thoracotomy for presumed early stage disease relapse
rapidly due to metastatic disease undetected by conven-
tional staging tests – so called “futile thoracotomy” [3].
Cancer staging depends on high technology imaging
platforms such as computerised tomography (CT),
positron emission tomography (PET) and magnetic res-
onance imaging (MRI), together with standard scintig-
raphy, plain X- rays and ultrasound. Staging pathways
are complex because these various modalities have
differing diagnostic accuracies across different tumour
types and body organs. The UK National Institute for
Health and Care Excellence (NICE) guidelines outline an
integrated but step-by-step sequential deployment of
various imaging modalities before tumour staging is
deemed complete and the first treatment decision is
made [4]. It is not unusual for a patient with colorectal
cancer to undergo CT chest, abdomen and pelvis, to-
gether with pelvic MRI in the case of rectal cancer, with
additional tests such as ultrasound, MRI and PET-CT
used increasingly in cases of known or suspected meta-
static disease. Similarly, it is not unusual for a patient
newly diagnosed with lung cancer to undergo standard
chest and abdominal CT, whole body PET-CT, brain CT,
and invasive mediastinal nodal sampling before the first
definitive treatment decision. This stepwise multi-
modality approach is both time and resource intensive,
and onerous for patients at a very difficult time. Further-
more, patients receive significant doses of ionising
radiation during the staging process that increase an
individual’s risk of subsequent malignancy [5].
Recent technological advances allow whole body MRI
scanning within one hour; sensitivity for metastatic
disease is reported to be high [6–10]. MRI does not use
ionising radiation and may be a safer, more efficient and
accurate alternative to the standard multi-modality
approach. There is little secondary research evidence
concerning the accuracy of whole body MRI (WB-MRI)
for cancer staging [11]. Meta- analysis is challenging be-
cause the WB-MRI primary literature comprises small
single-centre cohort studies across a wide variety of can-
cers. These limited data do however indicate potential as
an efficient and more accurate alternative for cancer sta-
ging. For example, NICE have recently recommended
WB-MRI as first line in the initial staging of myeloma,
due to higher accuracy compared to CT and standard
skeletal survey [12]. The vast majority of available stud-
ies are however single site, using one MRI platform, with
interpretation limited to one or two experienced radiolo-
gists. Generalisability is limited because most studies
investigate single modality comparisons (e.g. WB-MRI
vs. PET-CT) rather than comparing “real life” complex
multi-modality staging pathways. Moreover, studies
usually focus on diagnostic accuracy rather than thera-
peutic impact (i.e. the effect of testing on clinical
decision making). Other limitations include frequent
retrospective study designs, introducing bias.
This paper outlines the protocols of two multicentre
studies comparing WB-MRI to standard NICE-approved
diagnostic pathways for staging, (1) colorectal cancer –
Streamline C (ISRCTN no: 43,958,015) and, (2) non-
small cell lung cancer -Streamline L (ISCRTN no:
50,436,483). The studies are pragmatic and incorporate a
variety of MRI platforms and interpreting radiologists,
and assess the impact of WB-MRI on clinical decision
making in real-time. In addition, the trials incorporate a
health psychology assessment of patients’ experiences of
WB-MRI, investigating potential impact on the physical
and psychological burden of the cancer staging pathway,
Taylor et al. BMC Cancer  (2017) 17:299 Page 2 of 10
and predictors of patient preference. A detailed analysis
of the cost and the cost-effectiveness of WB-MRI versus
standard NICE-approved staging pathways will also be
conducted. These trials are funded by the UK National
Institute of Health Research (NIHR) Health Technology
Assessment (HTA) programme, sponsored by University
College London, and coordinated by the Cancer Research
UK and UCL Cancer Trials Centre.
Study objectives
Primary objective
To evaluate whether initial staging with whole body
magnetic resonance Imaging (WB-MRI) increases per
patient sensitivity for metastasis in colorectal and lung
cancer compared to standard NICE-approved diagnostic
pathways.
Secondary objectives
1) To determine how WB-MRI influences time to,
and nature of, the first major treatment decision
compared to standard investigations, and to
determine whether early WB-MRI could reduce or
replace standard investigations based on its
diagnostic accuracy.
2) To assess the accuracy of WB-MRI and standard
diagnostic pathways for local and distant cancer
staging. WB-MRI will be evaluated both as an
additional test to standard pathways, and as a
replacement test based per organ and per
metastasis analysis.
3) To determine the lifetime incremental cost and
cost-effectiveness of staging using WB-MRI
compared to standard diagnostic pathways.
4) To evaluate patients’ experiences of staging using
WB-MRI and to determine the priorities they place
on differing attributes offered by competing staging
pathways, including impact of reducing time to first
treatment.
5) To determine the inter-observer variability of
WB-MRI diagnosis of metastatic disease by different
radiologists and their confidence in diagnosis.
6) To evaluate the diagnostic accuracy of WB-MRI
protocols limited to diffusion and T1 weighted
imaging only, and to assess the incremental benefit
on diagnostic accuracy of intravenous gadolinium
contrast enhancement.
Methods
General
Streamline C and Streamline L are parallel multi-centre
prospective cohort studies comparing the staging accur-
acy of WB-MRI with standard pathways for newly diag-
nosed colorectal (Streamline C) and non-small cell lung
cancer (Streamline L) conducted at 25 English National
Health Service (NHS) hospitals. Data investigating the
therapeutic impact of WB-MRI on patient management
compared to standard pathways will be collated. The
trial design compares two different staging strategies in
the same patients ensuring comparable data are col-
lected for both pathways while simultaneously increasing
trial power to meet endpoints by using paired data.
Both qualitative and quantitative assessments will be
employed to determine the psychological burden and
acceptability of WB-MRI versus standard pathways, and
to identify those attributes that influence patient prefer-
ence most strongly. Health-related quality of life data
is being collected, which will be used to inform cost-
effectiveness modelling.
Inclusions/exclusion criteria
Inclusion and exclusion criteria are outlined below. A
series of imaging hubs will perform the WB-MRI
according to the trial protocol (see below). Patients will
be recruited from local hospitals (recruitment sites) and
referred to the closest imaging hub for the WB-MRI.
Some hospitals will act as both recruitment sites and im-
aging hubs.
In the colorectal cancer trial (Streamline C), eligible
patients are aged 18 or older, able to give written in-
formed consent, with histologically proven or strongly
suspected colorectal cancer referred for staging (the
latter defined as the presence of a mass highly suspicious
for colorectal cancer on endoscopy, barium enema, CT
colonography or other imaging which triggers staging
investigations).
Patients with polyp cancer will be excluded because
metastatic disease in these patients is exceedingly rare.
In the lung cancer trial (Streamline L), eligible patients
are aged 18 or older, able to give written informed
consent, with histologically proven or clinically diag-
nosed primary non-small cell lung cancer (NSCLC) with
potentially radically treatable disease. Clinically diag-
nosed NSCLC cancer is defined as radiological diagnosis
of lung cancer on chest CT with sufficient confidence to
trigger staging investigations. Potentially radically treat-
able disease is defined as stage IIIb or less on diagnostic
CT (i.e. T1–4, N0–2, M0). Patients should have a
performance status 0 to 2 inclusive (and fit to undergo
radical treatment if indicated). Patients with unequivocal
metastatic or N3 disease on diagnostic CT chest and
abdomen (including M1a disease; malignant pleural
effusion) will be excluded as will those in whom further
staging work up is not indicated due to poor perform-
ance status or patient choice. Those with histology other
than non-small cell lung cancer will also be excluded
given the differing biological behaviour of small cell
lung cancer.
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For both Streamline C and Streamline L, patients will
be excluded if they have any psychiatric or other dis-
order likely to impact on informed consent, or evidence
of severe or uncontrolled systemic disease, which make
it undesirable for the patient to participate in the trial.
Pregnant patients or others with contraindications to
MRI (e.g. cardiac pacemaker, severe claustrophobia,
inability to lie flat) are also excluded.
Ethical arrangements and consent
The Streamline trials were approved by the London –
Camden and King’s Cross Research Ethics Committee
on 3rd October 2012 and are being conducted in
accordance with the principles of ICH guidelines on
good clinical practice in clinical trials and the Research
Governance Framework for Health and Social Care
(England). All patients give written informed consent
prior to inclusion in the trials.
Diagnostic interventions
Whole body MRI (WB-MRI)
The choice of MRI platform (i.e. manufacturer and Tesla
(T) strength) will be decided by the local hub radiologist
according to scanner availability and their usual clinical
practice; either 1.5 T or 3 T platforms can be used.
WB-MRI will be performed no later than 3 weeks after
the final standard staging investigation. A minimum
sequence dataset will be acquired including standard T1,
T2 axial sequences supplemented by diffusion weighted
(minimum 2 b-values, 50 and 900 s/mm2) and contrast
enhanced T1 images through the liver, lungs and brain.
Standard imaging
Recruited patients will undergo all standard staging
investigations employed at their hospital as per local
protocols and requirements for usual care. The nature
and date of these standard investigations (e.g. CT scan,
PET-CT, organ specific MRI, biopsy etc.) will be
recorded, along with the presence and location of any
metastatic disease based on the radiological report, for
later comparison.
Blinding of WB-MRI reporters
WB-MRI will be reported by radiologists blinded to the
results of standard imaging tests and other clinical infor-
mation (other than the cancer diagnosis and site of the
primary tumour). A novel approach employing a secure
central imaging server (3Dnet™) provided by Biotro-
nics3D (London, UK) has been employed to ensure the
required level of blinding. Specifically, WB-MRI datasets
will be anonymised by radiographer/technologists before
upload from each hub to the secure central imaging
server (3Dnet™). This solution enables rapid and simple
upload of complex imaging datasets via a standard
internet connection. Unanonymised WB-MRI images
will only be released to the hospital picture and archiv-
ing system (PACS) after their revelation at the multi-
disciplinary team (MDT) meeting (see below) so those
reporting standard staging investigations are blinded to
the WB-MRI images and findings.
Interpretation and reporting
WB-MRI will be interpreted by designated trial radiolo-
gists who have prior experience in interpretation, de-
fined as at least 20 validated WB-MRI cases in patients
with lung or colon cancer. Radiologists with experience
of less than 100 WB-MRI datasets will in addition
undergo a period of “buddy” reporting with a more
experienced radiologist (>100 WB-MRI datasets), and
will only report alone once deemed competent by the
more experienced radiologist. Interpretation may be
performed using the 3Dnet™ viewing software or local
workstations after download of the WB-MRI images,
according to radiologist preference. A sequential viewing
paradigm with ordered reading of selected sequences
will used to examine the contribution of individual
MRI sequences to radiologist diagnostic confidence
and accuracy.
A free text clinical report will be produced based on
all available sequences containing information relating to
the local tumour (T), its nodal (N) stage, together with
the presence, location, number and size of any meta-
static deposits (M), as well as clinically important
incidental findings, for example aortic aneurysm. The
radiologist may recommend additional tests for equivo-
cal findings as per their routine clinical practice.
MDT review and influence of imaging on patient
management
As per usual clinical practice, the MDT meeting will
review all standard staging imaging initially blinded to
the WB-MRI findings. MDT meetings will occur at least
fortnightly, and usually weekly in a dedicated meeting
room and as a minimum will include a radiologist, on-
cologist, histopathologist and respiratory physician and/
or surgeon (Streamline L) or colorectal surgeon (Stream-
line C). It is anticipated that most MDT meetings will
include more than one representative of these special-
ities. The MDT will have access to the full clinical
record and histopathological data via the patient notes
or electronic patient record, together with all standard
imaging and reports via PACS. Based on this alone, the
MDT will document the first major treatment decision
(e.g. referral for surgical excision of the primary tumour,
instigation of definitive treatment using chemotherapy,
palliative/supportive care etc), as per usual care, along
with the TMN stage.
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The WB-MRI report and images will then be revealed
to the MDT members by the MDT coordinator or desig-
nated representative via 3Dnet™ using an internet
enabled PC (or via written paper copies in cases of IT
failure). MDT members will evaluate the WB-MRI re-
port and document any additional tests they deem the
WB-MRI result generates (if any). If these additional
tests have already been performed as part of the stand-
ard investigations, the MDT will then document the
theoretical first major treatment decision based on the
WB-MRI and results of the tests it would have gener-
ated. Finally, the MDT will then document their defini-
tive first major treatment decision based on all available
information (including the WB-MRI).
If the additional tests generated by the WB-MRI result
have not already been performed as part of standard in-
vestigations and are deemed necessary by the MDT,
these will be performed and the patients re discussed at
the next scheduled MDT meeting when the process
described above will be followed.
Occasionally a patient may commence definitive treat-
ment before the date of a scheduled MDT such that the
WB-MRI (and/or generated additional tests) will not yet
have been revealed to the MDT. In this scenario, an ad
hoc MDT will be convened consisting of all specialities
relevant to the patient’s clinical care, and the MDT
process described above will be followed.
Early release of WB-MRI findings
The WB-MRI images and reports may be released early
by reporting radiologists (ie before controlled revelation
at the MDT meeting) if a diagnosis is made that poten-
tially requires urgent intervention (specifically impend-
ing spinal cord compression, deep vein thrombosis or
pulmonary embolism, or brain metastasis with signifi-
cant mass effect requiring immediate treatment), or on
request of the patient’s lead clinician for the patient’s
clinical care in an emergency clinical situation. If early
release precludes unbiased MDT assessment of the
standard staging investigations, then the patient will be
replaced.
Time for staging
The total time taken to fully stage the patient using
standard staging pathways will be calculated from the re-
quest date of the first staging investigation to the date of
the MDT meeting’s first major treatment decision based
on the standard imaging pathway. For Streamline L, the
start of the staging process will be defined as the request
date of the first staging investigation following a proven
or highly suspected diagnosis of lung cancer (for ex-
ample the date of requested PET/CT after diagnostic
chest CT). For Streamline C, the start of the staging
process will be defined as the request date of the first
staging investigation following a proven or highly
suspected diagnosis of colorectal cancer (for example
the date of request for CT chest, abdomen and pelvis
after colonoscopic diagnosis of likely malignant tumour).
Because revelation of WB-MRI is deferred until after
standard staging is complete, precise measurement of
time to full staging using WB-MRI will not be possible.
The theoretical time to complete staging using WB-MRI
will be thus modelled taking into consideration the time
from recruitment date to the date of the WB-MRI, plus
the number and type of additional staging investigations
generated by WB-MRI.
Patient follow-up
Patients will be followed for a period of 12 months from
the date of consent. Patients are asked to complete a re-
source use diary every 3 months (recording all hospital
and GP visits, community care, medications and investi-
gations) and complete a validated general health
questionnaire (EQ-5D) (http://www.euroqol.org/) every
three months for subsequent health economic analysis.
Health psychology assessment
Health psychology assessment is essential for compre-
hensive evaluation of cancer staging pathways. A subset
of up to 25 patients for each cancer type will be inter-
viewed to determine their experience of WB-MRI and
standard staging tests, and also cancer staging pathways
in general. Interviews will assess which aspects of testing
cause patients most physical or psychological stress (e.g.
number of tests/ hospital visits, test attributes such as
claustrophobia, need to lie still, etc.), and will elicit any
factors that patients feel would have made staging easier.
These qualitative data will inform the design of a patient
experience questionnaire and, thereafter, a discrete
choice experiment (DCE). It is planned to administer
the questionnaire until 50 patient responses are collated
both before and after the WB-MRI, by which point we
anticipate saturation will have occurred. The DCE will
be targeted at 50 patients for each cancer type and aims
to elicit preferences for staging pathways by estimating
the relative importance of different attributes, and the
trade-offs between them. WB-MRI and standard staging
pathways differ in associated attributes, not only related
to physical experience but also rate of adverse events,
time to diagnosis, and overall accuracy etc. The most
important attributes will be identified in the interview
and questionnaire studies and appropriate levels
assigned to each based on accumulating data from the
trials, together with appropriate literature review. A
DCE questionnaire will be developed whereby patients
state their preference between two choices, with each
choice containing different levels of the identified attri-
butes. Comparisons will be repeated a number of times
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depending on the number of attributes and levels
identified.
Sample size for the discrete choice experiment should
be greater than (500*c)/(t*a) where t = the number of
sets of choices, a = the number of scenarios to choose
between in each choice, and c = the largest number of
levels for any one attribute. Assuming each patient will
undertake 15 sets of choices, there are two scenarios in
each choice, and the largest number of levels for any
one attribute is 3, the required sample size is (500*3)/
(15*2) = 50 per cancer type.
Further questionnaires including patient satisfaction,
the positive and negative affect schedule (PANAS) [13]
and the General Health Questionnaire (GHQ-12) [14]
will be administered during and after staging pathways,
and at three and six months later to examine how
patient test preferences may change as their treatment
trajectory progresses.
Clinical follow-up
MDT records and hospital data repositories will be used
over the 12-month follow-up period to collate primary
histological stage (where surgery performed), the results
of any biopsy procedure, and details and findings of
follow-up imaging investigations (in particular the pres-
ence or absence of metastasis). The date and cause of
patient death and post mortem findings (if performed)
will also be recorded.
Final reference standard for tumour stage
Multi-disciplinary consensus panel review is standard
methodology for diagnostic test accuracy studies where
an independent reference standard does not exist, or is
impossible because of incorporation bias. Consensus
panels will convene regularly to derive the reference
standard for tumour stage at diagnosis for recruited
patients completing 12-months of follow-up. The panels
will consider all available clinical information including
the results of all original standard staging investigations,
WB-MRI, histopathology (surgical resection and biop-
sies), follow up imaging, post-mortem reports (where
available) and MDT meeting records. Each panel con-
sists of at least an oncologist, and/or a colorectal sur-
geon, and a minimum of two radiologists, one external
to the recruitment site and one internal. At least one
radiologist must have specific expertise in WB-MRI and
in PET-CT. It is not necessary for this radiologist be
interpreting WB-MRI as part of the trials. The panel will
have access to a histopathologist if required. The
purpose of the panel is to adjudicate on the TNM stage
of the cancer at diagnosis, including the organ specific
sites and burden of metastatic spread against which the
accuracy of WB-MRI and standard staging pathways are
compared.
Cost effectiveness
Resource use data for the main drivers of hospital costs
will be collected from patient records, notably number
of outpatient visits, inpatient hospital stays, interven-
tional procedures including surgery, repeat imaging
investigations and treatment with chemotherapy or
radiotherapy. In addition, patients are requested to
complete resource use diaries at baseline, and at 3, 6,
and 9 months. The diaries will be used to collect data on
primary and community care contacts during the 1-year
period of follow up period. Additionally, health-related
quality of life score, measured according to the EQ-5D,
will be measured at baseline and at 3, 6, 9 and 12 months
for all surviving patients.
Outcome measures
Primary outcome measure
Per patient sensitivity for metastasis detection by WB-
MRI compared to standard staging pathways in newly
diagnosed colorectal and non-small cell lung cancer.
Secondary outcome measures
1. The time and test number taken to reach, and the
nature of, the first major treatment decision based
on WB-MRI compared to standard staging pathways
2. Diagnostic accuracy of WB-MRI and conventional
staging pathways for local tumour staging and
detection of metastasis. WB-MRI will be evaluated
both as an additional test to standard pathways per
patient, and as a replacement test based on per
organ and per metastasis analysis.
3. The lifetime incremental cost and cost-effectiveness
of staging using WB-MRI compared to standard
diagnostic pathways
4. Comparative patient experiences of staging using
WB-MRI and standard investigations, and the
average relative importance weighting of attributes
ascribed to standard versus WB-MRI staging
pathways.
5. Inter-observer variability in WB-MRI accuracy and
effect of radiologist diagnostic confidence on staging
accuracy.
6. Diagnostic accuracy of WB-MRI limited to T1 and
diffusion weighted sequences compared to full
WB-MRI protocols.
Sample size
For both trials, study power is based on a difference in
sensitivity for metastases detection, with the WB-MRI
pathway replacing the standard staging pathway. Both
trials are powered at 80% for type II error and 5% for
type 1 error. The sample size was calculated assuming
WB-MRI is more sensitive than standard staging
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pathways, and accounting for the expected prevalence of
metastasis in study cohorts [15].
For Streamline C, assuming WB-MRI has 10% greater
sensitivity for metastasis than standard pathways (85%
vs. 75%), a 40% prevalence of metastasis, 73% concord-
ance between WB-MRI and standard staging in patients
deemed to have metastatic disease by the consensus
panel, and assuming 10% withdrawal rate, we need to
recruit 322 patients, giving 290 evaluable patients (i.e.
patients with a cancer diagnosis and completing WB-
MRI with sufficient follow-up to assign a consensus
reference stage).
The initial recruitment target for Streamline L was 250
patients including 200 evaluable patients, based on 24%
greater WB-MRI sensitivity for metastasis (79% WB-
MRI, 55% standard staging), 25% prevalence of metasta-
sis and 53% concordance between WB-MRI and stand-
ard staging in patients deemed to have metastatic
disease by the consensus panel. A withdrawal rate of
20% was assumed.
During trial recruitment, and based on advice from
the independent data monitoring committee, recruit-
ment targets were increased to 360 (giving 290 evaluable
patients) for Streamline C and 353 (giving 200 evaluable
patients) for Streamline L because of higher than ex-
pected withdrawal rates of 19% and 43% respectively.
The higher withdrawal rate was predominantly due to
either a final non-cancer diagnosis, or failure to undergo
or complete the WB-MRI scan.
Analysis
A detailed statistical analysis plan will be produced and
finalised prior to data lock and transfer to trial statisti-
cian. Analysis will consider all patients in the study using
multiple imputation to account for missing data with a
sensitivity analysis based on complete case analysis.
Analysis for the primary outcome will use multivariate
logistic regression of paired binary outcomes for com-
parison of sensitivity and specificity of WB-MRI and
standard investigations within patients. 95% confidence
intervals will be calculated and p-values <0.05 will be
considered statistically significant. A similar approach
will be used for secondary outcomes.
There will be no adjustment of p-values for secondary
outcomes for multiple testing. STATA (Statacorp LP,
Texas, USA) statistical software will be used.
Health economic analysis will be performed by calcu-
lating (for each individual patient) the lifetime costs and
the quality-adjusted life-years (QALYs) experienced.
Costs extrapolated beyond the time horizon of one-year
follow-up will be deduced by development of a de novo
cost-effectiveness model for the disease pathways, which
will be populated via available evidence observed from
the trials. Individual patients will then be grouped
according to the specific disease path and the accuracy
of the staging result. We will calculate mean costs and
QALYs for each group and for WB-MRI versus standard
staging algorithms.
Analysis of health psychology interviews will unearth
the potential options for the health psychology question-
naire and the discrete choice experiment. Comparative
patient experience between WB-MRI and standard
staging investigations, identification of important staging
pathway attributes, comparative anxiety, expectations
and attribute importance before and following the
staging process will be analysed using appropriate com-
parative and regression statistics.
Discussion
At the time of writing, the Streamline trials are the lar-
gest prospective multicentre trials to directly compare
WB-MRI with standard imaging pathways for cancer
staging. The trials will be particularly informative
because they compare comprehensive staging pathways
rather than binary comparison of single imaging test
platforms. Pathway comparisons are made at relevant
points in the patient’s trajectory and recruits are repre-
sentative of patients undergoing WB-MRI in clinical
practice should it be introduced into the NHS. These tri-
als will therefore provide valuable information to guide
implementation of high technology imaging platforms
for cancer staging.
The trial design includes two important features:
methods to ensure blinding of those interpreting trial
imaging; and evaluation of the impact on therapeutic
management decisions made real time in the context of
the MDT meeting. The latter in particular is unusual in
imaging trials of this size. Furthermore, the trials include
a discrete choice experiment for patient preferences,
again an infrequent component of imaging technology
trials. We employ a reference standard based on consen-
sus panel meetings, to allow assessment of potential in-
corporation bias, as discussed below.
Blinding of trial imaging
Ascertaining the true standalone diagnostic accuracy of
a novel imaging test demands removal of certain exter-
nal influences on radiological decision making. Inter-
pretation of WB-MRI is likely to be influenced by
knowledge of other competing staging tests, to which
the reporting radiologists will therefore be blinded.
However, to mimic normal clinical practice, those
interpreting WB-MRI will not be blinded to the cancer
diagnosis nor the site of the primary tumour [16]. The
WB-MRI images and reports must not be immediately
available to those radiologists reporting the standard sta-
ging investigations, nor those involved in direct patient
care before the patient has been fully staged using
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standard investigations such that the first major
treatment decision can be made uninfluenced by the
WB-MRI findings. This approach ensures the standard
staging pathway are captured “intact” before revelation
of the WB-MRI results.
The PACS is the usual repository for imaging studies
in the NHS and accessible to many hospital staff. To
send un-anonymised WB-MRI images immediately to
the local PACS for reporting would potentially unmask
blinding. Instead, anonymised image data will be
uploaded at each imaging hub to a secure central
imaging server (3Dnet™) provided by Biotronics3D. A
computer based internet gateway will be installed in
each imaging hub to facilitate automated transfer of
WB-MRI from the scanner/workstation to 3Dnet™ for
reporting and storage, and thereafter automatically back
to PACS at the appropriate time point.
The 3Dnet™ server will also facilitate simple and timely
release of the WB-MRI report and images to the MDT
meeting without the need for CD transfer.
Comparison of real-time clinical impact of diagnostic
pathways
The trials are designed to compare the impact of the
WB-MRI staging pathway on patient management with
that based on standard imaging in the context of an
MDT. Impact is captured in real-time, contemporaneous
within the patients’ actual clinical care pathway deter-
mined at the MDT. This design also facilitates health
economic analysis as it provides prospective data on
patient management decisions made as a direct result of
the staging test results.
Specifically, WB-MRI imaging and reports are only
revealed once the MDT has committed itself to a full
staging and treatment decision based on standard inves-
tigations, but prior to any treatment being instigated.
After WB-MRI has been revealed the MDT will state
whether, based on WB-MRI alone, the patient had been
adequately staged or whether additional tests are re-
quired to clarify potential pathology indicated by WB-
MRI findings.
The final treatment plan for each patient will be based
on all available information, incorporating both standard
imaging pathways and WB-MRI. This design is neces-
sary because it would be unethical to not act on poten-
tially important WB-MRI findings. It will therefore be
possible to capture the following:
a. Treatment decision based on standard investigations
alone (and the number, timing nature and findings
of these investigations).
b. Treatment decision based onWB-MRI and any
additional staging investigations generated by the
WB-MRI (and the number, nature and findings of
additional tests generated).
c. Final treatment decision incorporating information
from all available tests.
In addition, record will be made of any complications
attributable to staging pathways, notably contrast
reactions, biopsy complications (infection, bleeding or
hospital admission), and delays in commencing definitive
treatment.
Consensus panel as reference standard and assessment of
incorporation bias
There is no single reference standard test for the initial
staging of lung and colorectal cancer. In such cases it is
acceptable design to convene a consensus to judge the
presence or absence of the target condition based on
multiple sources of information. In Streamline, panels
will consist of a variety of personnel from different disci-
plines allowing all imaging modalities and clinical data
to be discussed with equal emphasis informed by strict
guidance for the classification of new lesions identified
during the follow-up period, or indeterminate lesions.
To standardise panel decisions, a member of the cen-
tral trial team will attend each individual consensus
meeting to ensure similar criteria are used across centres
to define disease extent. The comparative findings of all
staging and follow up investigations (including all im-
aging) will be documented to allow estimation of any
potential incorporation bias in the final consensus panel
decision.
Discrete choice experiment
Discrete choice experiments (DCE) will be designed to
elicit patient preferences for the different attributes of
WB-MRI and conventional staging pathways (such as
time to diagnosis, exposure to radiation, overall accuracy
etc.) [17]. DCE designs elicits preferences from patients
regarding competing attributes. For example, what is
most important; a single visit to the hospital or a more
accurate testing pathway but which requires several
visits? Those attributes most important to patients will
be identified via interviews and questionnaires. Appro-
priate levels will be assigned to each based on accumu-
lating data from the trial and appropriate literature
review. This information will populate the DCE ques-
tionnaire which will ask patients to state their preference
between two competing choices, with each choice
containing different levels of the identified attributes.
Comparisons will be repeated a number of times de-
pending on the number of attributes and levels identified
in order to identify the “tipping” point, i.e. that point at
which the patient switches to favouring one attribute
over another.
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Conclusion
The Streamline colorectal and lung cancer trials are
multi-centre prospective cohort studies comparing the
diagnostic accuracy of WB-MRI with standard staging
tests for initial tumour staging. The trials include
important design features such as real time capture of
patient management decisions based on staging test
results, allowing impact comparisons for therapeutic
decision making. Novel approaches for blinding of image
interpretation are employed and in depth patient experi-
ence information will be collected to analyse the accept-
ability of the two separate pathways.
Trial status
The Streamline trials have completed recruitment.
Streamline C opened on 8th March 2013 and closed to
recruitment on 19th August 2016, recruiting 370
patients. Streamline L opened on 7th February 2013 and
closed to recruitment on 5th September 2016 recruiting
353 patients. The analysis plan described in this protocol
will be implemented in due course after data retention,
follow up and cleaning.
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